Cervical Cytology DNA Methylation for Cervical Cancer Screening

Launched by LEI LI · Aug 14, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to screen for cervical cancer that may be more effective than current methods. Researchers want to see if testing for certain changes in DNA, specifically looking at two genes (PAX1 and JAM3), can help identify women who are at risk for cervical cancer more accurately than traditional tests like HPV testing or cell examinations. The study will involve around 30,000 women and will use results from biopsies (tissue samples) as the main comparison to determine how well the new test works.

To participate in this trial, women must be at least 18 years old, have an intact uterus, and be willing to give consent to join the study. Participants will undergo the new screening test and will be monitored closely. This trial aims to improve cervical cancer screening processes, making them safer and more precise, ultimately helping to reduce the number of cases and avoid unnecessary treatments. It's an exciting opportunity for those eligible to contribute to important research that could change how cervical cancer is detected in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 years or older
• • With uterine cervix intact
• • Given consents to participate the study
• • With detailed follow-up outcomes
• Exclusion Criteria:
• • Not meeting all of the inclusion criteria